Cargando…
A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial
BACKGROUND AND AIMS: Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) are widely used for the treatment of type 2 diabetes, and recent studies indicate that they may be cardio- and neuroprotective. The safety and effect of a single dose of exenatide, a short-acting GLP-1RA, on cerebral an...
Autores principales: | Ölmestig, Joakim, Marlet, Ida R., Vilsbøll, Tina, Rungby, Jørgen, Rostrup, Egill, Lambertsen, Kate L., Kruuse, Christina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831269/ https://www.ncbi.nlm.nih.gov/pubmed/36636739 http://dx.doi.org/10.3389/fnagi.2022.899389 |
Ejemplares similares
-
Tadalafil may improve cerebral perfusion in small-vessel occlusion stroke—a pilot study
por: Ölmestig, Joakim, et al.
Publicado: (2020) -
The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial
por: Larsen, Emil List, et al.
Publicado: (2017) -
Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018) -
Effect of Home-Based High-Intensity Interval Training in Patients With Lacunar Stroke: A Randomized Controlled Trial
por: Steen Krawcyk, Rikke, et al.
Publicado: (2019) -
Altered somatosensory neurovascular response in patients with Becker muscular dystrophy
por: Lindberg, Ulrich, et al.
Publicado: (2018)